We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Wash and grow

9 February 2021 By Ed Cropley

Bain and Cinven are paying drugmaker Lonza $4.7 bln for its skin sanitiser-ingredient unit. Aided by leverage, the pair should be able to eke out an acceptable return. But that hinges on changes to personal hygiene trends rather than just cost-cutting.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)